Search results

Making a positive impact: NICE people and communities network case studies

Embed NICE content in your digital products and services with our syndication API.

Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.

Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.

Learn more about what NICE content is available for reuse by checking our information asset register.

Learn about situations where you cannot use NICE content.

Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.

RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.

How we collect and use your personal information, and your rights under data protection legislation.

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

Home What NICE does NICE International {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1

If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.

The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

A step-by-step timeline of the process we used to develop single technology appraisals (STA).